Personalized Initiatives Empower Patients to Actively Participate in Cancer Research
Investigators who champion patient-partnered cancer research have experienced challenges to their effective implementation.
Related Articles
Selinexor Shows Potential as Maintenance Therapy for TP53 Wild-Type, pMMR Endometrial Cancer
Debra L. Richardson, MD, FACS, FACOG, discusses how selinexor may address the need for effective maintenance therapies in pMMR, TP53 wild-type endometrial cancer.
FDA Approves New Dosage of Trastuzumab Biosimilar for HER2-Overexpressing Cancers
Following its initial approval at 150 mg, trastuzumab-strf has also been approved at 420 mg for the treatment of several HER2-overexpressing cancers.
Sylvester Annual Oncology Update Highlights Different Perspectives in Bladder Cancer, Other Treatment Areas
Janaki Neela Sharma, MD, discusses takeaways from the Sylvester Comprehensive Cancer Center 2024 Annual Oncology Update.
Leadership Course
The American Society for Transplantation and Cellular Therapy is an international professional membership association of more than 3,900 physicians, investigators and other health care professionals…
Post Hoc Analysis Reveals Potential Serum Glycoproteomic Biomarkers for Nivolumab/Cabozantinib in Advanced RCC
David A. Braun, MD, PhD, discusses the potential for protein glycosylation as a biomarker to predict nivolumab/cabozantinib responses in advanced RCC.
Fertility outcomes post immune checkpoint inhibitor exposure
Harrold et al. evaluate the fertility impact of checkpoint inhibitor blockade (ICB), demonstrating that unlike in utero exposure, post-exposure conception appears to result in uncomplicated pregnancies…
FDA Approves Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
The FDA has approved obecabtagene autoleucel for relapsed/ refractory B-cell precursor acute lymphoblastic leukemia.
Ep. 71 – Pazdur Unplugged: FDA Director Richard Pazdur on the Past, Future of Cancer Treatments
Richard Pazdur, director of FDA’s Oncology Center of Excellence, joined FDA in 1999. Looking back on his 25th anniversary, he draws a line between unpopular…
Clive Peedell (@drpeedell.bsky.social)
Consultant Clinical Oncologist NHS advocate and campaigner Politically centre left Wealth inequality creates health inequality
Ohio State’s Update From the 2024 San Antonio Breast Cancer Symposium 02/01/2025
Breast cancer experts from Ohio State and invited speakers will bring you the latest insights and practical guidance as presented at the 2024 San Antonio…
